Literature DB >> 8922723

Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue.

K Nasu1, N Moriyama, K Kawabe, G Tsujimoto, M Murai, T Tanaka, J Yano.   

Abstract

1. There are at least three alpha 1-adrenoceptor subtypes, alpha 1a, alpha 1b and alpha 1d, in human tissues. Using an RNase protection assay, we have now determined the amount of each subtype mRNA in human prostatic tissue, for both benign prostatic hypertrophy (BPH) and non-BPH. In all tissue samples examined, the predominant subtype mRNA was alpha 1a. The total abundance of alpha 1-adrenoceptor mRNA in BPH samples was over six times that in non-BPH samples. This increase was mostly accounted for by alpha 1a, which was almost nine times as abundant in BPH samples as in non-BPH samples. The abundance of alpha 1b was almost the same between BPH and non-BPH samples, and the abundance of alpha 1d in BPH samples was about three times that in non-BPH samples. The ratio of the numbers of the subtype mRNAs, alpha 1a: alpha 1b: alpha 1d, was 85:1:14 in BPH samples and 63:6:31 in non-BPH samples. 2. In situ hybridization studies showed no significant differences in the tissue localization of alpha 1-adrenoceptor subtype mRNAs between BPH and non-BPH samples. alpha 1a and alpha 1d were clearly detected in the interstitium of the prostate, where alpha 1a was stained more intensely than alpha 1d, and the positive sites were primarily smooth muscle cells. In contrast, alpha 1b staining was very faint. 3. This increase in mRNA abundance may be directly related to the contraction of prostatic tissue that leads to obstruction of the urinary tract in BPH patients. Specifically, our data suggest that increased expression of the alpha 1a subtype may be primarily responsible for the contraction of the prostate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8922723      PMCID: PMC1915954          DOI: 10.1111/j.1476-5381.1996.tb15742.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

Review 1.  Rationale for the use of alpha-blockers in the treatment of benign prostatic hyperplasia (BPH).

Authors:  K Kawabe; N Moriyama; S Yamada; N Taniguchi
Journal:  Int J Urol       Date:  1994-09       Impact factor: 3.369

2.  Sequence of a rat brain cDNA encoding an alpha-1B adrenergic receptor.

Authors:  M M Voigt; J Kispert; H M Chin
Journal:  Nucleic Acids Res       Date:  1990-02-25       Impact factor: 16.971

3.  Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor.

Authors:  S Cotecchia; D A Schwinn; R R Randall; R J Lefkowitz; M G Caron; B K Kobilka
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

4.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

5.  A molecular titration assay to measure transcript prevalence levels.

Authors:  J J Lee; N A Costlow
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

6.  A membrane-filter technique for the detection of complementary DNA.

Authors:  D T Denhardt
Journal:  Biochem Biophys Res Commun       Date:  1966-06-13       Impact factor: 3.575

7.  Bladder outflow obstruction treated with phenoxybenzamine.

Authors:  P H Abrams; P J Shah; R Stone; R G Choa
Journal:  Br J Urol       Date:  1982-10

8.  Comparison of alpha 1-adrenergic receptor subtypes distinguished by chlorethylclonidine and WB 4101.

Authors:  K P Minneman; C Han; P W Abel
Journal:  Mol Pharmacol       Date:  1988-05       Impact factor: 4.436

9.  Alpha 1-adrenoceptor subtypes in the human prostate.

Authors:  C R Chapple; R P Burt; P O Andersson; P Greengrass; M Wyllie; I Marshall
Journal:  Br J Urol       Date:  1994-11

10.  Pharmacological characterization of alpha 1-adrenoceptor subtypes in the human prostate: functional and binding studies.

Authors:  I Muramatsu; M Oshita; T Ohmura; S Kigoshi; H Akino; M Gobara; K Okada
Journal:  Br J Urol       Date:  1994-11
View more
  28 in total

1.  Effects of castration on contraction and alpha(1)-adrenoceptor expression in rat prostate.

Authors:  Y Homma; K Hamada; Y Nakayama; G Tsujimoto; K Kawabe
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.

Authors:  Vincent M Santillo; Franklin C Lowe
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine.

Authors:  Yoshiyuki Kojima; Shoichi Sasaki; Yutaro Hayashi; Gozoh Tsujimoto; Kenjiro Kohri
Journal:  Nat Clin Pract Urol       Date:  2009-01

4.  Pharmacological characterization of N1-(2-methoxyphenyl)-N4-hexylpiperazine as a multi-target antagonist of α1A/α1D-adrenoceptors and 5-HT1A receptors that blocks prostate contraction and cell growth.

Authors:  Fernanda Chagas-Silva; Jéssica Barbosa Nascimento-Viana; Luiz Antonio S Romeiro; Luana C Barberato; François Noël; Claudia Lucia Martins Silva
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-10       Impact factor: 3.000

Review 5.  Phenotype pharmacology of lower urinary tract α(1)-adrenoceptors.

Authors:  A Nishimune; H Yoshiki; J Uwada; A S M Anisuzzaman; H Umada; I Muramatsu
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 6.  Silodosin in the treatment of benign prostatic hyperplasia.

Authors:  Maxime Rossi; Thierry Roumeguère
Journal:  Drug Des Devel Ther       Date:  2010-10-27       Impact factor: 4.162

Review 7.  Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

Authors:  Martin C Michel; Wim Vrydag
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 8.  Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction.

Authors:  Serap Gur; Philip J Kadowitz; Wayne J G Hellstrom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  The alpha1A-adrenoceptor gene is required for the alpha1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate.

Authors:  Kt Gray; Jl Short; S Ventura
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

10.  Caveolae contribute to the apoptosis resistance induced by the alpha(1A)-adrenoceptor in androgen-independent prostate cancer cells.

Authors:  Maria Katsogiannou; Charbel El Boustany; Florian Gackiere; Philippe Delcourt; Anne Athias; Pascal Mariot; Etienne Dewailly; Nathalie Jouy; Christophe Lamaze; Gabriel Bidaux; Brigitte Mauroy; Natalia Prevarskaya; Christian Slomianny
Journal:  PLoS One       Date:  2009-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.